Introduction
Oestrogens play an important role in the development of breast cancer (Colditz, 1998; Dickson and Stancel, 2000; Clemons and Goss, 2001 ) and stimulate both the proliferation and survival of breast cancer cells (Colditz, 1998; Foster et al., 2001; Mandlekar and Kong, 2001) . Adjuvant hormonal therapies such as Tamoxifen counter the actions of oestrogens and reduce the probability of death and recurrence in those with breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1998) . The actions of oestrogens and antioestrogens are mediated by two receptors, oestrogen receptor alpha (ERa) and the more recently identified oestrogen receptor beta (ERb), which bind to oestrogen response elements (ERE) in the promoters of target genes and function as ligand-dependent transcription factors. Identifying factors that influence ER function will increase our understanding of key mechanisms involved in the development of breast cancer and may provide strategies to improve hormonal therapy.
BAG-1 is a multifunctional protein that modulates the activity of a range of important cell control pathways. Overexpression of BAG-1 protects cells from a wide range of apoptotic stimuli, activates RAF-1, enhances metastasis and proliferation and regulates transcription (Bardelli et al., 1996; Wang et al., 1996; Clevenger et al., 1997; Schulz et al., 1997; Takaoka et al., 1997; Froesch et al., 1998; Hohfeld, 1998; Kullmann et al., 1998; Yawata et al., 1998; Yang et al., 1999b; Guzey et al., 2000; Cato and Mink, 2001; Niyaz et al., 2001; Takayama and Reed, 2001) . Interaction with 70 kDa heat-shock proteins is considered to be a key for many of these functions (Briknarova et al., 2001) . BAG-1 exists in human cells as three major isoforms with apparent molecular weights of approximately 36, 46 and 50 kDa (Packham et al., 1997; Takayama et al., 1998; Yang et al., 1998; Brimmell et al., 1999) , described here as BAG-1S, BAG-1M and BAG-1L, respectively. BAG-1 isoforms are generated by alternate translation initiation of a single mRNA (Packham et al., 1997; Takayama et al., 1998; Yang et al., 1998; Coldwell et al., 2001 ) and therefore share a common C-terminus with the larger isoforms having additional N-terminal sequences. The unique N-terminus of BAG-1L contains a nuclear localization sequence and is predominantly located within the nucleus, whereas BAG-1S is predominantly a cytoplasmic protein and BAG-1M partitions between the nucleus and cytoplasm (Packham et al., 1997; Takayama et al., 1998; Yang et al., 1998; Brimmell et al., 1999; Knee et al., 2001) .
BAG-1 isoforms bind and regulate the activity of several nuclear hormone receptors (NHR), including the androgen receptor, the thyroid hormone receptor, the vitamin D receptor, the glucocorticoid receptor and the retinoic acid receptor Kullmann et al., 1998; Liu et al., 1998; Guzey et al., 2000; Cato and Mink, 2001; Takayama and Reed, 2001; Witcher et al., 2001) . In addition, BAG-1L activates transcription from a range of promoters apart from those associated with NHR, and BAG-1M produces similar effects following heat shock (Zeiner et al., 1999; Niyaz et al., 2001) . Activation or repression of NHR function by BAG-1 is frequently isoform specific. For example, BAG-1L, but not BAG-1S and BAG-1M, increases androgen receptor function . By contrast, BAG-1M and BAG-1L, but not BAG-1S, inhibit glucocorticoid receptor activity (Kullmann et al., 1998) . It is likely that, at least in part, BAG-1 functions via HSC70/HSP70 since chaperone molecules are important for NHR function (Pratt and Toft, 1997; Cheung and Smith, 2000) , and BAG-1 function is often (Briknarova et al., 2001) , but not always (Liu et al., 1998) , dependent on BAG-1 C-terminal regions and residues important for chaperone binding. BAG-1 may act to regulate the refolding of receptors by HSC70/HSP70 required when changing from ligand-bound to ligand-free conformations. It has been suggested that BAG-1-mediated modulation of androgen receptor function may be of relevance to mechanisms by which prostate cancers become resistant to hormonal therapies , and this may also be the case with the ER in breast cancer. Although it has been demonstrated that BAG-1M interacts with ERa in vitro (Zeiner and Gehring, 1995) , it is not known whether BAG-1 isoforms bind ERa and regulate receptor function in cells.
Several studies have reported alterations in expression of BAG-1 in breast cancer Brimmell et al., 1999; Tang et al., 1999; Yang et al., 1999b; Turner et al., 2001; Townsend et al., 2002) . Yang et al. showed high levels of BAG-1L in both normal and breast cancer tissues by immunoblotting, while BAG-1S was elevated in breast cancer tissue compared to normal breast tissue (Yang et al., 1999a) . Turner et al. (2001) reported that cytoplasmic, but not nuclear, BAG-1 overexpression was associated with improved overall survival in both univariate and multivariate analysis in early-stage breast cancer. However, the published literature on the clinical significance of BAG-1 expression is conflicting (Cutress et al., 2001) . For example, an earlier study from our group demonstrated that nuclear BAG-1 expression was associated with lower histological grade, and although we observed a trend for patients with nuclear BAG-1 expression to have better outcomes, this did not reach statistical significance . Tang et al. (1999) also reported that BAG-1 expression and in particular nuclear BAG-1 expression was associated with well-differentiated tumours. However, in multivariate analysis, they found that BAG-1 expression was associated with decreased disease free and overall survival. Since BAG-1 is multifunctional, it is possible that the significance of BAG-1 expression may vary in tumours treated with differing adjuvant therapies . The conflicting reports on the clinical significance of BAG-1 might stem, at least in part, from studying patient groups with heterogeneous treatment regimens.
Given the importance of hormonal therapy for breast cancer and the possible impact of BAG-1 on ER function, we studied the effect of BAG-1 expression on ER-dependent transcription. We also analysed the relation between BAG-1 expression, and expression of ERa and the progesterone receptor (PgR), an ER transcriptional target (Horwitz et al., 1978) , and clinico-pathological features in a relatively homogeneous cohort of consecutive breast cancer patients treated with adjuvant hormonal therapy.
Results

Effect of BAG-1 on oestrogen-dependent transcription
Since the BAG-1 cDNA encodes all BAG-1 isoforms, we first mutated the BAG-1 cDNA to produce isoformspecific expression constructs for the major BAG-1 isoforms (see Materials and methods). Immunoblot analysis demonstrated that MCF7 breast cancer cells transfected with each of these isoform-specific constructs expressed approximately equivalent levels of the appropriate isoforms ( Figure 1a) .
We used reporter assays to determine whether BAG-1 isoform expression regulated the ability of 17b-oestradiol to stimulate ER-dependent transcription. ER-positive MCF7 cells were cotransfected with an ERE-containing luciferase reporter gene construct and with expression plasmids encoding one of the three human BAG-1 isoforms, or pcDNA3 as a control. The reporter construct was modestly stimulated by 17b-oestradiol (10 pm) in cells cotransfected with the control plasmid, pcDNA3. Coexpression of BAG-1L significantly enhanced transcriptional responses to 17b-oestradiol (P ¼ 0.005), whereas BAG-1S and BAG-1M had no effect, although expressed at equivalent levels ( Figure 1b) . Titration experiments were performed to determine the optimal amount of BAG-1 expression construct for stimulation of oestrogen-dependent transcription: experiments shown were performed using amounts of expression construct that gave maximum stimulation. The effects of BAG1-L were dose-dependent since reducing the amount to expression construct resulted in decreased transcription (data not shown). The effects of BAG-1L and oestrogen were specific since neither 17b-oestradiol nor any of the BAG-1 isoforms had any effect on the expression of luciferase in cells transfected with a control reporter construct lacking ERE (Figure 1c ). In addition, BAG-1L did not increase expression of the CMV promoter within the b-galactosidase expression construct used to control for transfection efficiency relative to pcDNA3, BAG-1S or BAG-1M (data not shown). In oestrogen dose response experiments, cells overexpressing BAG-1L were more sensitive to 17b-oestradiol at all concentrations (Figure 2) . In control cells, approximately 10 pm 17b-oestradiol was required to produce half-maximal activation of transcription, whereas this level of transcription was reached in cells overexpressing BAG-1L at approximately 2 pm 17b-oestradiol. Therefore, MCF7 cells overexpressing BAG-1L were up to approximately fivefold more sensitive to oestrogens. The concentrations of 17b-oestradiol (1-10 pm) where BAG-1L produced the most significant stimulation of ER function are within the physiological range.
MCF7 cells express both ERa and ERb and further experiments were performed using ER-negative 293 cells to determine whether the activity of both receptors was regulated by BAG-1 isoforms. Cells were transfected with the BAG-1 expression plasmids, the ERE reporter and expression constructs for ERa or ERb and then stimulated with 17b-oestradiol (10 pm for ERa, 100 pm for ERb) or left untreated as a control (Figure 3 ). BAG-1L potentiated ER-dependent transcription in cells transfected with ERa or ERb although the overall level of transcription was more modest in cells expressing ERb. There was also some increase in transcription in the absence of added hormone in some experiments. Enhancement of transcription by BAG-1L was dependent on the presence of ER, demonstrating that the effect was mediated through the receptor (data not shown) and was not due to altered receptor expression since coexpression of BAG-1L did not significantly alter expression levels of ERa (data not shown and Figure 5 ). Similar to results obtained in MCF7 cells, BAG-1S and BAG-1M did not stimulate the activity of either receptor (data not shown and Figure 7b ). Therefore, BAG-1L stimulates the activity of both ERa and ERb.
BAG-1 interaction with ERa
We performed coimmunoprecipitation experiments using MCF7 cells to determine whether endogenous BAG-1 and ERa proteins interacted in cells. BAG-1 isoforms were immunoprecipitated and the precipitates analysed by immunoblotting ( Figure 4 ). We readily detected interaction of BAG-1 with its direct binding partner HSC70 and also with ERa. However, the proportion of total ERa bound to BAG-1 was relatively low (B2%). The BAG-1 antibody detects all isoforms and we therefore performed overexpression studies in 293 cells to determine which BAG-1 isoform interacted with ERa ( Figure 5 ). 293 cells express low levels of BAG-1 and we were unable to demonstrate significant interaction of endogenous BAG-1 with HSC70. However, when BAG-1 isoforms were overexpressed, significant binding to HSC70 was detected. Similar to HSC70, there was no interaction detected between endogenous BAG-1 and ERa. However, when BAG-1L was overexpressed, we detected interaction between BAG-1L and ERa. Although all BAG-1 isoforms interacted with HSC70, only BAG-1L associated with ERa. BAG-1L also interacted with ERb in transfected 293 cells (data not shown).
Effect of targeting BAG-1S to the nucleus
The ability of BAG-1L, but not other BAG-1 isoforms, to interact with ERs and stimulate oestrogen-dependent transcription may stem from the colocalization of BAG-1L and ER in the nucleus. To determine whether targeting BAG-1S to the nucleus was sufficient to stimulate ER-dependent transcription, we generated an expression construct in which the BAG-1S coding sequence was fused to an heterologous nuclear localization sequence. By immunoblot analysis, the NLS-BAG-1S protein was expressed at similar levels to other BAG-1 constructs (data not shown). Immunofluorescence analysis demonstrated that when overexpressed, BAG-1S was generally localized diffusely throughout the cell, whereas BAG-1L and NLS-BAG-1S were largely present in the nucleus. Data are shown for MCF7 cells (Figure 6a ) because their morphology more clearly allows discrimination between nuclear and cytoplasmic distribution, and similar data were obtained in 293 cells. However, targeting BAG-1S to the nucleus was not Interaction between endogenous BAG-1 and ERa. Lysates were prepared from MCF7 cells and proteins immunoprecipitated using BAG-1-specific antiserum TB2 (lanes 2) or preimmune serum as a control (lanes 3). The immunoprecipitates were analysed by immunoblotting using the indicated antibodies. Lanes 1, whole-cell lysate (10% of input to immunoprecipitation) Figure 5 Specific interaction of BAG-1L and ERa. 293 cells were cotransfected with an ERa expression construct and BAG-1 isoform expression constructs or pcDNA3. BAG-1 proteins were immunoprecipitated using BAG-1-specific polyclonal antibody TB2 (lanes 3) and immunoprecipitated proteins analysed by immunoblotting using the indicated antibodies. Lanes 1, wholecell lysate (10% of input to immunoprecipitation), and lanes 2 immunoprecipitation with preimmune serum as a control BAG-1 expression and ER function RI Cutress et al sufficient to stimulate oestrogen-dependent transcription ( Figure 6b ).
Expression of BAG-1 in breast cancer
Our results suggested that BAG-1L can regulate ER function in breast cancer cell lines, and we therefore wished to determine the importance of BAG-1 and its relation to ER function in human breast cancer. We have argued that the impact of a multifunctional protein like BAG-1 on survival in breast cancer might depend on the specific treatment regimens applied and we therefore selected a relatively homogeneous cohort of 138 patients who had received hormonal therapy after resection of their tumour (Table 1 ). The histological diagnosis was invasive ductal carcinoma in 112(81%) patients, invasive lobular carcinoma in 10(7%) patients and other types of invasive breast carcinoma in 16 (12%) patients. The tumours were analysed for expression of BAG-1 (Figure 7 ), ERa and PgR, a transcriptional target of ER and a clinical marker of ER activity in breast cancer samples. Nuclear BAG-1 expression was moderately correlated with PgR (Po0.001, r ¼ 0.42) and with ERa expression (P ¼ 0.02, r ¼ 0.31). As expected, ERa expression also correlated moderately with PgR expression (Po0.001, r ¼ 0.52). Although there was also a strong correlation between nuclear and cytoplasmic BAG-1 expression (Po0.001, r ¼ 0.74), the association between cytoplasmic BAG-1 expression and PgR and ERa was marginally weaker (Po0.001, r ¼ 0.32 and P ¼ 0.003, r ¼ 0.30, respectively) compared to nuclear BAG-1 expression.
We also compared expression of BAG-1 with clinically relevant parameters and outcome. All of the patients received hormonal therapy and none received chemotherapy. A total of 54 patients (39%) were treated surgically by mastectomy and 84 patients (61%) by breast-conserving surgery. In addition, 92 (67%) patients underwent axillary dissection. Breast radiotherapy was given in the majority of cases treated by breast-conserving surgery. The standard first-line adjuvant hormone therapy was Tamoxifen (20 mg/day), but patients were occasionally changed to Anastrozole (1 mg/day) if Tamoxifen was not tolerated. There was a strong inverse association between nuclear BAG-1 Figure 6 Effects of NLS-BAG-1S on oestrogen-dependent transcription (a) MCF7 cells were transfected with expression constructs for BAG-1S, NLS-BAG-1S or BAG-1L, or pcDNA3 as a control. BAG-1 expression was detected using the TB2 polyclonal BAG-1-specific antibody (Brimmell et al., 1999) The impact of BAG-1 on survival was demonstrated using Kaplan-Meier plots (Figure 8) . Of the 123 patients with known BAG-1 status, 24 patients died of breast cancer and three patients died from other causes. Positive (H-score4100) nuclear, but not positive cytoplasmic, BAG-1 labelling was associated with significantly increased survival in single-variable analysis (P ¼ 0.015) (Table 1) . Surprisingly, axillary status did not reach significance in single-variable analysis, but approximately one-third of patients did not undergo axillary dissection, and so axillary status was unavailable in these cases.
Discussion
Alterations in BAG-1 expression occur in a variety of tumour types Tang et al., 1999; Yang et al., 1999a; Shindoh et al., 2000; Rorke et al., 2001; Turner et al., 2001; Yamauchi et al., 2001; Hague et al., 2002; Townsend et al., 2002) , and BAG-1 overexpression may play an important role in breast cancer development. Here we show that BAG-1L is a potentially important regulator of the ERs, both in breast cancer cell lines and primary breast cancers.
BAG-1L, but not BAG-1S or BAG-1M, significantly enhanced transcriptional response to oestrogens. Our studies suggest that cells overexpressing BAG-1L may be approximately fivefold more sensitive to oestrogens, and high levels of BAG-1L would therefore be expected to have a major impact on the growth and survival of breast cancer cells. Consistent with this, nuclear BAG-1 expression was correlated with PgR, a clinical measure of ER function. Similar to the androgen receptor (Froesch et al., 1998; Knee et al., 2001) , the specific 
BAG-1 expression and ER function
RI Cutress et al ability of the BAG-1L isoform to activate ERa function correlated with its unique ability to interact with the receptors. The colocalization of ER and BAG-1L in the nucleus does not explain the specific effects of BAG-1L, since targeting BAG-1S to the nucleus is not sufficient to stimulate oestrogen-dependent transcription. Thus, similar to the androgen , additional functions provided by the N-terminus, which contains a region rich in basic amino-acid residues that mediates nonspecific DNA binding (Zeiner et al., 1999) , may be required. BAG-1 proteins interact with HSC70 in breast cancer cells and the interaction between BAG-1L and the ER may be mediated through these chaperones. Since chaperone molecules are important for NHR function, this may explain how BAG-1L enhances ER function. However, further studies are required to determine the exact mechanism of action of BAG-1L on ER function. Although BAG-1L and BAG-1M have been shown to increase general transcription and the activity of the CMV promoter in some settings (Zeiner et al., 1999; Niyaz et al., 2001) , the activation of ERE-dependent transcription reported here was specific since it was absolutely dependent on ERE. BAG-1 isoforms did not increase activity of TK-promoter reporter constructs lacking ERE and BAG-1L and did not effect expression of the CMV promoter within the b-galactosidase expression construct used to control for transfection efficiency relative to BAG-1S-or BAG-1M-transfected cells. It has also been demonstrated that BAG-1L overexpression increases ERa transcription in HeLa cells (Niyaz et al., 2001) and it remains possible that enhanced expression of ERa may contribute to the effects of BAG-1L on ER-dependent transcription in some settings. However, in 293 cells, expression of ERa was maximally increased 1.5-fold in cells overexpressing BAG-1L, whereas ER activity was 410-fold increased. Moreover, the effects of BAG-1L were similar in MCF7 cells which express endogenous ERa and 293 cells where ERa was expressed from an expression plasmid containing a constitutive promoter in place of the natural ERa promoter sequences.
Previous studies of the clinical significance of BAG-1 expression in breast cancer have produced conflicting results (Tang et al., 1999; Cutress et al., 2001; Turner et al., 2001; Townsend et al., 2002) and this may stem, at least in part, from differences in the treatment regimens in various patient cohorts . Here, we have shown that patients treated with hormonal therapy whose tumours expressed nuclear BAG-1 enjoyed better outcome than those who did not. We also found a strong inverse correlation between nuclear BAG-1 expression and tumour grade and a moderate association between nuclear BAG-1 expression and ERa and PgR expression. Therefore, our study suggests that there is a group of ERa-and PgR-positive tumours with high levels of nuclear BAG-1, and these patients respond relatively well to hormone therapy. Consistent with this, the PgR is a transcriptional target of ERa (Horwitz et al., 1978) and combined with ERa may better predict response to hormone therapy (Horowitz and McGuire, 1975; American Society of Clinical Oncology, 1996) . Although BAG-1 status was predictive of outcome in single-variable analysis, and predictive of outcome independent of tumour size and grade and patient age in limited multiple variable analysis (data not shown), this could not be confirmed in multiple variable analysis including all variables. The reduced power of our multiple variable model when all variables were included was due to the fact that a significant proportion of the cohort had not undergone axillary surgery leading to a reduction in the number of evaluable cases and events. Further work is therefore required to confirm if the predictive value of nuclear BAG-1 status in patients treated with hormonal therapy is independent of other parameters.
The correlation detected here between BAG-1 expression and ERa was found in a subset of patients in our earlier study, where we also found a correlation with tumour grade, and a tendency for improved outcome in patients with high levels of nuclear BAG-1 . Tang et al. (1999) , found in contrast that nuclear BAG-1 expression conferred worse prognosis in multivariate analysis. In this study, we used the same antibody as Turner et al. (2001) , but did not detect the correlation between high levels of cytoplasmic BAG-1 expression and good prognosis that they reported. We found a strong correlation between nuclear and cytoplasmic BAG-1 expression however and so it is possible that slight differences in the immunohistochemical and scoring techniques used between these studies account for some of the differences. It is also likely that some of the variation reported for the effect of BAG-1 on survival stems from the different cohorts studied. The patient cohort studied by Turner was younger and less frequently treated with hormone therapy compared to our cohort, and a proportion was also treated with chemotherapy. Future studies should focus on the impact of BAG-1 in well-defined patient cohorts or be sufficiently large to allow meaningful subgroup analysis.
Our results may help to explain why patients with high level nuclear BAG-1 expression do relatively well when treated with hormonal therapies. Since BAG-1L significantly increases the activity of ERa, high levels of nuclear BAG-1 may indicate tumours that are highly dependent on ERa-mediated signalling pathways for survival and proliferation. These tumours would be more responsive to the growth inhibitory and proapoptotic effects of hormonal therapies. Therefore, nuclear BAG-1 may be a marker of ERa function (via its direct effects on receptor function), similar to PgR (as a downstream measure of receptor activity). Conversely, decreased nuclear BAG-1 expression might identify patients who respond poorly to hormone therapy, as seen with loss of ERa expression. However, it is important to recognize that the antibody used to detect BAG-1 in breast cancer sample detects all BAG-1 isoforms and it is possible that a proportion of nuclear BAG-1 staining in breast cancer cells is due to relocalization of BAG-1S or BAG-1M from the cytoplasm to the nucleus. Analysis with BAG-1L-specific antibodies may provide additional information about the relation between BAG-1 isoforms and outcome in breast cancer, if reagents of sufficient quality for immunohistochemical analysis become available.
Although only BAG-1L was able to interact with ER and potentiate oestrogen-dependent transcription, BAG-1S and BAG-1M are also likely to play important roles in breast cancer. For example, we have demonstrated that overexpression of BAG-1S prevents longterm stress-induced growth inhibition in breast cancer cells (PAT, RC, GP, manuscript submitted), and relative to control transfected cells, BAG-1S overexpression in mouse breast cancer xenograft models leads to increased tumour size (Kudoh et al., 2002) . BAG-1S also inhibits all trans-retinoic acid-induced apoptosis in breast cancer-derived cell lines (Liu et al., 1998) . Although differentially localized in the cell, it is also possible that BAG-1S might indirectly influence the ability of BAG-1L to potentiate transcritpion, perhaps by competing for shared binding partners. Therefore, there is an emerging picture and increasing evidence that BAG-1 may play several important roles in the development and progression of breast cancer. Consistent with this, we and others have previously reported correlations of BAG-1 expression with clinicopathological features and clinical outcome in breast cancer (Tang et al., 1999; Turner et al., 2001; Townsend et al., 2002) and we now show here that nuclear BAG-1 expression correlates with outcome in patients treated with adjuvant hormone therapy. BAG-1 may therefore prove to be an attractive target for novel anticancer treatments.
Materials and methods
Plasmids
The BAG-1S expression construct was generated by inserting an EheI fragment containing the human BAG-1S open reading frame in to the EcoRV site of pcDNA3 (Invitrogen, Paisley, UK). The BAG-1M and L expression plasmids were generated by optimizing the translation start sites for each isoform to repress translation from downstream start sites. The BAG-1M expression construct was generated by replacing the HindIII to XcmI fragment of plasmid pcDNA3-BAG-1S with a PCR product containing an optimized BAG-1M translation start site (generated by PCR using primers p46/M (CCCAAGCTTGAATTCCGCCATGGCGAAGAAGAAA-ACCCGGCGCCG) and 3 0 NESTED (CGCCATTTCCTCC-CTGGTCACCTC) (Oswel, Southampton, UK). The BAG-1L expression construct was generated in a similar way using a PCR product containing an optimized BAG-1L translation start site (generated by PCR using primers p50/L-r (CCAAAGCTTGAATTCCGCCATGGCTCAGCGCGGG-GGGGCGC) and 3 0 NESTED in plasmids pcDNA3-BAG-1S. The NLS-BAG-1S expression construct was generated by amplifying the BAG-1S cDNA with primers p36 NLS (CCCAAGCTTGAATTCGAAGAGATGCCAAAAAAGA-AGAGAAAGGTAAATCGGAGCCAGGAGGTG) and BAG-1 C-term (CCGCTCGAGTGCTACACCTCACTCG-GCCAGGGC), digesting the PCR product with HindIII and XhoI and cloning into pcDNA3 which had been linearized using the same enzymes. The ERE3TKluc reporter plasmid contains three copies of an ERE cloned upstream of the minimal HSV-1 TK promoter and luciferase reporter gene and was a kind gift of Dr S Ali (Imperial College, London, UK). The TKluc plasmid that lacks ERE sequences was used as a control. The b-galactosidase expression plasmid CMV-b-gal was from Invitrogen.
Reporter assays
MCF7 human breast cancer cells (ER positive) were maintained in Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) supplemented with 10% (v/v) foetal calf serum and antibiotics. For reporter studies, cells were cultured in phenolred-free Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% (v/v) charcoal dextran-treated serum (Hyclone, Perbio Science Ltd, Tattenhall, UK) for 3 days prior to plating. The following day, cells were transfected using the Fugene 6 reagent (Roche, Lewes, UK) according to the manufacturer's instructions. All transfections contained a constant amount of a CMV-b-galactosidase expression plasmid, and b-galactosidase activity was used to control for variations in transfection efficiency and nonspecific effects on transcription. A typical transfection would comprise 3.3 mg of pcDNA3-based expression plasmid, 1.7 mg of CMV-b-gal and 1.7 mg of luciferase reporter construct. For 293 cells, a typical transfection would comprise 3.3 mg of pcDNA3-based expression plasmid, 1.32 mg of ERa or ERb expression plasmid (or empty pSG-5 vector as control), 1.32 mg of luciferase reporter construct and 0.66 mg of CMV-b-gal. The Fugene 6 to DNA ratio was 3 : 1 and the Fugene 6/DNA complex was removed after 5 h. At 16 h after transfection, cells were trypsinized and plated in 60 mm dishes at 2 Â 10 5 cells per dish. After 5 h, the media were replaced with media containing 17b-oestradiol at the appropriate concentration, or media without added 17b-oestradiol. The following day, cells were harvested and analysed for b-galactosidase and luciferase activity.
Interaction assay
To analyse interaction of BAG-1 and endogenous ERa, MCF7 cells were plated in medium containing phenol red and complete serum and harvested the following day. Cells were resuspended in HMKEN buffer (HEPES (4-(2-hydroxy-ethyl)-piperazine-1-ethane-sulphonic acid) pH 7.2, 10 mm, MgCl 2 5 mm, KCl 142 mm, EGTA (ethylene glycol-bis(2-aminoethyl)-N,N,N 0 ,N 0 -tetraacetic acid) 2 mm, Nonidet P40 0.2% (v/v), Protease Inhibitor Cocktail (Sigma, UK) 1/100) by trituration through a 21 gauge needle, lysed on ice for 30 min and clarified by centrifugation (12 000 rpm for 10 min). One-tenth of the lysate was retained as a whole-cell lysate. The remaining sample was precleared using protein G sepharose beads for 30 min at 41C. Protein G sepharose beads were removed by centrifugation. The lysate was divided and incubated with the BAG-1-specific rabbit polyclonal antibody, TB2 (Brimmell et al., 1999 ) (5 ml per 900 ml lysate) or with preimmune control serum (5 ml per 900 ml lysate) at 41C for 16 h. The immunecomplexes were incubated with protein G sepharose beads for 1 h and removed by centrifugation. The beads were washed five times using HMKEN, resuspended in SDS-PAGE sample buffer and heated at 951C for 5 min. Primary antibodies used were 3.10 G3E2 hybridoma supernatant (Brimmell et al., 1999) for BAG-1, C314 (Santa Cruz Biotechnology, CA 95060, USA) or NCL-6F11 (Vector Laboratories Ltd, Newcastle, UK) for ERa and B6 for HSC70 (Santa Cruz). To analyse specific interactions of BAG-1 isoforms with ERa, HEK 293 cells were transfected using Fugene 6 reagent (Roche). Cells were transfected with BAG-1 and ERa (pSG5-HEGO, Pace et al., 1997; kind gifts of Dr S Ali, Imperial College, London, UK) expression plasmids. Control transfections were per-formed using an equivalent amount of empty vector. Immunoprecipitations and immunoblotting were performed as described above.
Immunoflourescent microscopy MCF7 cells were grown on glass coverslips and transfected with appropriate expression constructs. The following day, cells were washed twice in phosphate-buffered saline (PBS) and fixed in PBS containing 4% (w/v) paraformaldehyde and 3% (w/v) sucrose for 15 min at room temperature. Cells were washed with PBS and incubated with PBS containing 10% (v/ v) newborn calf serum (NCS) and 0.05% (w/v) sodium azide for 20 min at 41C. Cells were washed and permeabilized by incubation in permeabilization buffer (PBS containing 10% (v/v) NCS and 1% (v/v) Triton X-100) for 20 min at room temperature. Cells were washed and then incubated with the polyclonal anti-BAG-1 antibody TB2 (Brimmell et al., 1999) diluted 1 : 1000 in permeabilization buffer for 20 min at room temperature. Cells were washed and incubated with 2 mg/ml FITC-conjugated anti-rabbit immunoglobulins (Sigma) diluted in permeabilization buffer for 1 h at room temperature. Cells were then washed in PBS and mounted on glass slide using Flourescent Mounting Media (Dako). Cells were visualized on an Axiovert 100 flourescent microscope (Zeiss).
Cohort selection
Following local Research Ethics Committee approval (Southampton and South West Hants Local Research Ethics Committee; Submission Number: 159/00), 144 patients were studied. Consecutive patients with available tissue blocks diagnosed with primary invasive breast carcinoma between the years of 1990 and 1995 were included in the study. Patients included received surgery, followed by adjuvant hormone therapy but not chemotherapy. Six cases were excluded since their tissue failed to produce any labelling with any antibody on multiple occasions (including internal positive control). The median follow-up was 5 years 7 months.
Immunohistochemistry
Immunohistochemistry was performed using 4 mm sections. The sections were deparaffinized for 10 min in xylene and washed in 100% alcohol through to 70% for 1 min in each. Endogenous peroxidase activity was blocked using 3% (v/v) hydrogen peroxide in methanol for 15 min. Antigen retrieval was performed using microwave treatment in 0.01 m citrate buffer (pH 6.0) for 25 min at medium power for BAG-1 and PgR, or pressure cooker treatment for 2 min at full pressure in 0.01 m citrate buffer for ERa. BAG-1-specific monoclonal antibody KS6-C8 (Dako, Ely, UK) was used at 1 : 100 dilution and has been used previously for immunohistochemical analysis of BAG-1 of archival material (Turner et al., 2001) . The specificity of this antibody has been confirmed by multiple techniques : Turner et al., 2001 . Moreover, KS6-C8 and a second BAG-1-specific monoclonal antibody, 3.10 G3E2 (Brimmell et al., 1999) , gave essentially identical patterns of reactivity in immunohistochemical analysis of breast cancer sections (data not shown). ER and PgR were detected using 1D5 (Dako) and PgR636 (Dako) antibodies, respectively, both at 1 : 200 dilution. Sections were incubated in primary antibodies diluted in Tris-buffered saline (TS: 10 mm Tris-HCl pH 8.0, 150 mm NaCl) overnight at 41C. Sections were warmed to room temperature, washed in TS and incubated with biotinylated anti-immunoglobulins (Biogenex, CA 94583, USA) at 1 : 50 dilution in TS for 30 min. The sections were washed in TS and incubated with horseradish peroxidase-conjugated streptavidin (Biogenex) at 1 : 50 dilution in TS for 30 min. Sections were then washed in TS and incubated with diaminobenzidine substrate (Biogenex) for 10 min, washed in tap water and counter-stained in Harris's haematoxylin before being differentiated in acid alcohol, blued in tap water, dehydrated and mounted with coverslips. Negative controls lacking primary antibody and batch controls using sections known to give intermediate labelling were included on each staining run.
Assessment of tissue labelling
An intensity-proportion score (H-score) was used to analyse immunostaining (Kinsel et al., 1989) . The labelling intensity of each section was allocated a value of 0 (no labelling), 1 (weak), 2 (intermediate) or 3 (strong) and was multiplied by the percentage of positive cells (nuclear labelling for ERa and PgR; nuclear and cytoplasmic labelling assessed separately for BAG-1) to give a maximum possible score of 300. For analysis of ERa and PgR, an H-score of X75 was considered positive since this value has been previously used in the clinical assessment of ERa status. We considered an H-score of 4100 as positive for nuclear or cytoplasmic BAG-1. Where immunostaining was patchy we assessed the area of most intense labelling. We used benign breast epithelium in each section as a positive internal control for all of the antibodies. Sections where the tumour appeared negative but there was also no labelling of the benign tissue were restained. A total of 15 tumour samples were completely negative (including normal breast epithelium) on repeated analysis for BAG-1 expression although expression of ERa or PgR was detected in these samples. Since normal breast epithelium has been consistently reported to be BAG-1 positive in previous studies Brimmell et al., 1999; Yang et al., 1999a) , the BAG-1 status of these cases was classified as unknown.
Statistics
Statistical analysis was performed using SPSS for windows version 10 (SPSS inc., Chicago, USA). Pearson's w 2 test and w 2 test for trend were used to assess associations between BAG-1 status and tumour grade, lymph node status and size. Pearson's correlation coefficient was used to assess correlation between nuclear and cytoplasmic BAG-1 H-scores, and nuclear BAG-1 H-scores and ERa and PgR H-scores. Kaplan-Meier plots were used to demonstrate survival over the period of the study. The effect on survival of various prognostic factors including BAG-1 status was assessed using Cox proportional hazards regression. The assumption of proportional hazards was checked graphically by plotting log-minus-log of survival functions. Single and multiple variable analyses of nuclear and cytoplasmic BAG-1 were performed using a cutoff value of 100. The Wald test was used to determine the statistical significance of exploratory variables. Two-sample t tests were used to test the significance of differences in transcriptional activity in the reporter assays.
